Supercharged immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT06193486

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests a new approach for men with metastatic castration-resistant prostate cancer that has spread to the bone and no longer responds to standard treatments. Researchers take a patient's own immune cells (gamma delta T cells), genetically modify them to recognize and attack prostate cancer cells, and infuse them back. The study aims to find the safest dose and see if the treatment can shrink tumors or lower PSA levels.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically engineered gamma delta T cells targeting prostate stem cell antigen
What this could lead to: If it works, this could point toward a new treatment option for men with advanced prostate cancer that has stopped responding to standard therapies.
What could go wrong: This is a very early phase 1 trial with only 30 participants, so it is not yet known if the treatment is safe or effective. There are also risks from the chemotherapy given beforehand and potential side effects from the engineered cells.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.